OncoSec Medical Inc.
Company Snapshot: OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.
- Sep 4 2018 OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
- Aug 31 2018 OncoSec to Present at H.C. Wainwright 20th Annual Global Investment Conference
- Aug 28 2018 OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
- Aug 6 2018 OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.